Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marko Skelin

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|May 1, 2019
Platelet Counts and Risk of Major Bleeding With IbrutinibMarko Lucijanic, Marko Skelin
JAMA Oncology|September 27, 2019
Longer Survival With Anti-Programmed Cell Death 1 and Development of Cutaneous Toxic Effects, an Expected AssociationMarko Skelin, Marko Lucijanic
The New England Journal of Medicine|October 31, 2019
Liraglutide in Children and Teens with Type 2 DiabetesEugen Javor, Marko Skelin, Marko Lucijanić
JAMA Oncology|January 17, 2020
Association of Early Palliative Care With Survival in Patients With Advanced Lung CancerMarko Skelin, Eugen Javor, Marko Lucijanic
European Journal of Heart Failure|December 5, 2019
Dyslipidaemia, a factor worthy of adjustmentMarko Skelin, Marko Lucijanic, Jelena Lucijanic
JAMA Oncology|May 3, 2019
Aspirin Use and the Risk of CancerMarko Skelin, Eugen Javor, Marko Lucijanic
JAMA|April 19, 2022
Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory DiseasesEugen Javor, Goran Hauser, Marko Skelin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2020
Dietary Supplement Use and Patient Outcomes in High-Risk Early-Stage Breast CancerEugen Javor, Marko Lucijanić, Marko Skelin
Biochemia Medica|April 11, 2017
Survival analysis, more than meets the eyeMarko Lucijanic, Marko Skelin, Tomo Lucijanic
European Journal of Hospital Pharmacy : Science and Practice|December 23, 2025
Correspondence on "Stability of alglucosidase alfa in 0.9% sodium chloride for enzyme replacement therapy in patients with Pompe disease: insights from enzyme activity and cellular uptake measurements" by Barzel <i>et al</i>Andrej Belančić, Eugen Javor, Marko Skelin
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Clinical Lymphoma, Myeloma & Leukemia|May 1, 2019
Platelet Counts and Risk of Major Bleeding With IbrutinibMarko Lucijanic, Marko Skelin
JAMA Oncology|September 27, 2019
Longer Survival With Anti-Programmed Cell Death 1 and Development of Cutaneous Toxic Effects, an Expected AssociationMarko Skelin, Marko Lucijanic
The New England Journal of Medicine|October 31, 2019
Liraglutide in Children and Teens with Type 2 DiabetesEugen Javor, Marko Skelin, Marko Lucijanić
JAMA Oncology|January 17, 2020
Association of Early Palliative Care With Survival in Patients With Advanced Lung CancerMarko Skelin, Eugen Javor, Marko Lucijanic
European Journal of Heart Failure|December 5, 2019
Dyslipidaemia, a factor worthy of adjustmentMarko Skelin, Marko Lucijanic, Jelena Lucijanic
JAMA Oncology|May 3, 2019
Aspirin Use and the Risk of CancerMarko Skelin, Eugen Javor, Marko Lucijanic
JAMA|April 19, 2022
Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory DiseasesEugen Javor, Goran Hauser, Marko Skelin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2020
Dietary Supplement Use and Patient Outcomes in High-Risk Early-Stage Breast CancerEugen Javor, Marko Lucijanić, Marko Skelin
Biochemia Medica|April 11, 2017
Survival analysis, more than meets the eyeMarko Lucijanic, Marko Skelin, Tomo Lucijanic
European Journal of Hospital Pharmacy : Science and Practice|December 23, 2025
Correspondence on "Stability of alglucosidase alfa in 0.9% sodium chloride for enzyme replacement therapy in patients with Pompe disease: insights from enzyme activity and cellular uptake measurements" by Barzel <i>et al</i>Andrej Belančić, Eugen Javor, Marko Skelin
Pageof 7